ROBERTO SIRVEN: Open Payments
NPI 1902235476 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,900 in 118 payments from 19 companies in 2025. Trend: 2023 $2,355 · 2024 $2,650 · 2025 $2,900
Food & beverage: $2,866Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 27 | $653 |
| GlaxoSmithKline, LLC. | 15 | $323 |
| CSL Behring | 7 | $245 |
| Galderma Laboratories, L.P. | 9 | $243 |
| BioCryst US Sales Co., LLC | 12 | $226 |
| Novartis Pharmaceuticals Corporation | 5 | $218 |
| Regeneron Healthcare Solutions, Inc. | 9 | $189 |
| Amgen Inc. | 8 | $172 |
| GENZYME CORPORATION | 6 | $151 |
| Optinose US, Inc. | 5 | $128 |
Products named: DUPIXENT, TEZSPIRE, XOLAIR, NEMLUVIO, FASENRA, ORLADEYO, Andembry, NUCALA.
Industry payments across FL — which companies pay providers there.
